Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP)
- 9 August 2005
- Vol. 24 (3) , 293-303
- https://doi.org/10.1016/j.vaccine.2005.07.074
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Immune-based therapies for prostate cancerImmunology Letters, 2004
- Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer (E7897): A Trial of the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2004
- Eligibility and Outcomes Reporting Guidelines for Clinical Trials for Patients in the State of a Rising Prostate-Specific Antigen: Recommendations From the Prostate-Specific Antigen Working GroupJournal of Clinical Oncology, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Molecular Cloning of a Novel Human Acid Phosphatase Gene (ACPT) That Is Highly Expressed in the TestisGenomics, 2001
- Naturally occurring prostate cancer antigen‐specific T cell responses of a Th1 Phenotype can be detected in patients with prostate cancerThe Prostate, 2001
- ANTIBODY IMMUNITY TO PROSTATE CANCER ASSOCIATED ANTIGENS CAN BE DETECTED IN THE SERUM OF PATIENTS WITH PROSTATE CANCERJournal of Urology, 2000
- Primary structure of rat secretory acid phosphatase and comparison to other acid phosphatasesGene, 1990
- High Degree of Homology Between Primary Structure of Human Lysosomal Acid Phosphatase and Human Prostatic Acid PhosphataseBiological Chemistry Hoppe-Seyler, 1989
- Comparative Toxicity of Halothane, Isoflurane, Hypoxia, and Phenobarbital Induction in Monolayer Cultures of Rat HepatocytesAnesthesiology, 1988